Key Takeaways
- Soft quarter, confident tone: Revenue declined 31.7% YoY as a large cyclical order rolled off, but management called the worst behind and guided for positive YoY growth in Q4.
- Margins held up despite the top-line drop: Normalized EBITDA margin expanded to 10.2% from 8.1% YoY, supported by favorable mix and operational efficiencies, with further expansion expected as volumes return.
- The order book is rebuilding on better-quality work: Three consecutive quarters of order book growth, driven by aerospace, industrial and medical segments, with management stating the new orders carry better margins than historically delivered.
- Build-to-Spec is the next margin lever: B2S revenue commenced and is expected to reach a double-digit mix in FY'27, with meaningful contribution from FY'28 onward, carrying healthy gross margins and higher volumes.
- What to watch next quarter: Whether Q4 delivers the promised positive YoY growth, whether order inflow returns to the ~₹500 crore run-rate, and whether the two new sales hires convert pipeline into bookings within the guided two-quarter lag.
Revenue: The Hole and the Rebuild
- The FY'25 comp problem: The 31.7% YoY revenue decline is primarily the completion of a large cyclical order in FY'25, not a broad-based demand collapse. The base effect is now largely behind.
- Tariff uncertainty froze customers: Customers entered wait-and-watch mode around the tariff situation before picking up inventory, causing Q3 push-outs. Those push-outs are already on track to ship in Q4 with no prolonged impact expected.
- Q4 return to growth: Management is confident of positive year-over-year growth in Q4, with momentum carrying into FY'27.
- FY'27 growth assumption: Management confirmed a 20% to 25% growth assumption for FY'27 as correct.
- Order inflow recovery: Q4 order inflow is expected to return to Q1/Q2 levels of approximately ₹500 crore, and the order book trajectory will continue to grow.
Krishna Bodanapu: "I believe the worst, if I may, is behind us, at least from a revenue perspective."
Margins: Quality Over Quantity
- Normalized margin expansion: Adjusted EBITDA margin expanded to 10.2% from 8.1% YoY, driven by favorable revenue mix and strong operational and supply chain efficiencies. The quality of revenue has significantly improved.
- One-off adjustments: Reported margin reflects two items: M&A evaluation expenses (₹1.78 crore) for a deal that did not materialize, and a wage impact (₹1.63 crore) from the new Government of India wage code. Neither reflects the normal business run rate.
- Mix shift supporting margins: Industry mix is now more balanced, with healthy contributions from aerospace, industrial and medical segments after the large defense order completed. Product mix is shifting toward box build, mechanical and other value-added services, contributing positively to margin expansion.
- Operating leverage ahead: As volumes scale in coming quarters, management expects operating leverage to further enhance margins through better utilization, improved absorption and a more optimized cost structure.
- Q4 and FY'27 margin guide: Margins are expected to be slightly more than Q3's double-digit levels in both Q4 and FY'27.
Rajendra Velagapudi: "whatever order book we have today, so based on the order book, margins are going to be better than what we had currently."
Order Book & Strategic Pipeline
- Three quarters of growth: The order book has grown for three consecutive quarters, driven mainly from the India side of business, not Altek. Growth is concentrated in aerospace, industrial and medical segments, not defense.
- New logos added: Two new customers added in Q3: one in medical (battery management systems for medical applications) and one in industrial (high-precision electrical motor controls). Two more were added in each of the prior two quarters.
- Strategic opportunities in Q4: A few strategic opportunities in advanced stages moved into Q4, with management confident of converting them in the near term.
- Sales engine building: Key strategic sales resources are being added, with many already joined and a few more expected before year-end. Management expects benefits to compound over the next few quarters, with a probable two-quarter lag before new hires show order intake.
- Next-gen product engagements: Four anchor customers are involving Cyient DLM in developing next-generation products: two from transportation, one from industrial, one from defense. Revenues are expected to begin within two years and meaningfully contribute from FY'28 onward, supported by healthy gross margins and higher volumes.
Rajendra Velagapudi: "We expect revenues from these programs to begin within 2 years, supported by healthy gross margins and higher volumes. These engagements represent a significant long-term opportunity and are expected to meaningfully contribute to our financials from FY '28 onwards."
Build-to-Spec: The Margin Story
- Revenue commenced: Cyient DLM has begun revenue realization from Build-to-Spec (B2S) programs, marking the start of a higher-value service offering beyond traditional build-to-print.
- FY'27 mix target: B2S is expected to grow to a double-digit percentage of revenue in FY'27, with good growth continuing into FY'28 and margins going up as the mix shifts.
- Clear runway for scale: Management sees a clear runway for significant scale-up of B2S programs in coming quarters as the programs mature.
- Margin driver alongside mix: Both the industry mix change toward aerospace, industrial and medical, and the B2S growth are expected to drive margin improvement going forward.
Balance Sheet & Working Capital
- Net cash position: The company is net cash positive, with the ability to draw an additional ₹350-400 crore from a pure working capital perspective. Dry powder is available for capital expansions or acquisitions.
- Working capital temporarily elevated: Net working capital rose primarily due to inventory buildup from customer-specific shipment delays in Q3 and inventory buildup for Q4 shipments. DIO is expected to ease by year-end, and overall NWC levels are expected to normalize in Q4 and beyond.
- Capex light model: Regular maintenance capex runs at 1% to 2% of revenues. Additional customer-specific capex can be deployed quickly with available dry powder.
- M&A still on the radar: Management continues to look for both organic and inorganic expansion, including strengthening presence in Europe. A recent international acquisition opportunity was pursued but called off because terms did not fit expectations.
R. M. Subramanian: "We are net cash positive. So we have ability to go up to, from a pure working capital perspective, another INR350 crores to INR400 crores."
Tariffs & Geographic Exposure
- Q3 tariff impact was small: The U.S. tariff impact in Q3 was not huge, per management.
- Mitigation options presented: Four options have been presented to U.S. customers to reduce tariff impact, though management did not disclose what portion of U.S.-bound shipments are paying the 50% tariff.
- Geographic mix shifting: India contribution is rising, but Rest of World continues to be higher, driven by long-standing customers and new additions in North America and Europe.
- Revenue diversification target: Over the next two to three years, revenue will be diversified across aerospace and defense, industrial, medical, and automotive, likely slightly higher on aerospace and defense but otherwise equally distributed.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Positive year-over-year growth | Q4 FY26 |
| FY'27 revenue growth | 20% to 25% growth | FY'27 |
| Order inflow | Return to Q1/Q2 levels (~₹500 crore) | Q4 FY26 |
| EBITDA margin | Slightly more than Q3's double-digit level | Q4 FY26 and FY'27 |
| Build-to-Spec mix | Double-digit percentage of revenue | FY'27 |
| Next-gen product revenue | Meaningful contribution to financials | FY'28 onwards |
| Net working capital | Normalization | Q4 FY26 and beyond |
| Sales team impact | New hires to show order intake | Within ~2 quarters |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹303.3 cr, 31.7% YoY decline |
| Order book | ₹2,350 cr, QoQ increase of ₹58.3 cr |
| Order intake | ₹387 cr |
| Book-to-bill ratio | 1.3x for Q3; 1.56x YTD |
| EBITDA (reported) | ₹27.5 cr, 9.1% of revenue |
| EBITDA (normalized) | ₹30.9 cr, 10.2% margin, 207 bps higher YoY |
| PAT (normalized) | ₹13.8 cr, 18.6% YoY decline; margin 4.6%, 73 bps higher YoY |
| PAT (reported) | ₹11.2 cr, 3.7% of revenue |
| Build-to-spec revenue mix | ~6% to 7% of FY26 revenue |
| New customer logos added | 2 (medical and industrial) |
| IPO proceeds utilized | 93.2% as of Dec 2025; working capital 97.2%, capex 15.4% |
| One-off: M&A evaluation expense | $17.75 mn expensed in Q3 |
| One-off: Wage code impact | ₹1.63 cr expensed in Q3 |
| Balance sheet capacity for additional working capital | ₹350 cr to ₹400 cr |
| Regular capex run rate | 1% to 2% of revenue |